Results of treatment of primary carcinoma of the lung

Stanford, William; Spivey, Charles G.; Larsen, Gordon L.; Alexander, James A.; Besich, William J.

doi:10.1016/s0022-5223(19)40074-3

Cited by 30 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When comparing the survivals of the present Roswell Park Memorial Institute series with the previous studies (Table II), it can be seen that the picture now is substantially better than before [I]. The comparison of the survival figures of the present study with those of other studies in Table I1 shows that the present figures approach the lower range of the other results [2,3,6,7,9,10]. Since many of those studies did not state whether their series include the postoperative death or cancer only the survivors of the postoperative period, we have added the survival curve which excludes the postoperative deaths ( Fig.…”

Section: Peleg Et A1supporting

confidence: 55%

Prognosis after resection of non‐small cell lung cancer of the right middle lobe

Peleg

Antkowiak

Lane

et al. 1987

Journal of Surgical Oncology

View full text Add to dashboard Cite

In a previous study at Roswell Park Memorial Institute, it was noted that in patients whose resected non-small-cell lung cancer had originated in the right middle lobe, the prognosis was much worse than when it had originated in any other lobe. A review of a longer period and exclusion of patients who might introduce a bias resulted in a group of 18 patients whose fate was compared to the findings reported in other comparable series. Three out of those are alive at 8-96 months after operation. Five-year survival was 22% (30% counting only survivors of the operations). These findings indicate that the results of surgery for non-small-cell carcinoma of the right middle lobe fall within the lower range of lung cancer generally.

show abstract

Section: Peleg Et A1supporting

confidence: 55%

Prognosis after resection of non‐small cell lung cancer of the right middle lobe

Peleg

Antkowiak

Lane

et al. 1987

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Current five‐year survivals following resection are markedly better. In 1976, in a series of over 1,000 patients from the American armed forces, Stanford et al 4 reported an overall five‐year survival of 48.8% in patients having definitive surgery. Kadri 5 reported a British series of 479 cases having definitive surgery, with a five‐year survival of 39.8%.…”

Section: Lung Surgery In Britainmentioning

confidence: 99%

The treatment of lung cancer

Dussek

1991

Int J Clinical Practice

View full text Add to dashboard Cite

“…Lung cancer incidence has shown a considerable increase in the statistics of the industrialized countries within the last few decades [Tserkovny et al, 1975;Chaklin et al, 1976;Napalkov et al, 1977, etc.]. from satisfactory [Paulson, Reisch, 1976;Slanford et al, 1976;Peterson, 1977;Wagner, Barchuk, 1978, etc. ].…”

Section: Introductionmentioning

confidence: 99%

On the end results of surgical treatment of lung cancer patients depending on the type of anesthetic agent

Wagner

Frid

Evtukhin

et al. 1981

Journal of Surgical Oncology

View full text Add to dashboard Cite

The end results of therapy of 346 patients with lung tumors, treated with surgery alone, are compared, depending on the type of general anesthetic agent used. Anesthesia was induced with ether in 220 patients, halothane in 103, and neuroleptanalgesia in 23 cases. All the anesthetic agents were administered in a mixture with nitrous oxide. The basic characteristics of patients, who were divided on the basis of anesthetic agent, were identical. The results show that type of anesthesia during surgical treatment for lung tumor has an effect on the end results of therapy, and the best prognosis is ensured when halothane is used. Further analysis established that the end results of surgery with halothane anesthesia are improved, when partial resection rather than radical pneumonectomy is performed, at stage 2 of malignant disease and when metastases into regional lymph nodes are absent. Such improvement may be explained by stimulation of the hypothalamo-pituitary-adrenal system as well as a relatively lower degree of immunosuppression and development of conditions more adverse for implantation of circulating tumor cells than in the case of ether or neuroleptanalgetic anesthesia.

show abstract

Results of treatment of primary carcinoma of the lung

Cited by 30 publications

References 15 publications

Prognosis after resection of non‐small cell lung cancer of the right middle lobe

Prognosis after resection of non‐small cell lung cancer of the right middle lobe

The treatment of lung cancer

On the end results of surgical treatment of lung cancer patients depending on the type of anesthetic agent

Contact Info

Product

Resources

About